AbbVie partners with Valkai to apply AI in clinical development
AbbVie (ABBV) partnered with Valkai to apply advanced AI across targeted areas of clinical development.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AbbVie Inc. (ABBV) Partners With Valkai to Apply AI in Clinical Development
AbbVie entered a partnership with Valkai to deploy AI tools across targeted areas of clinical research to improve efficiency, speed insights and support opportunities to reduce development timelines.Material DetailsContext by AI AnalystThis is an early-stage strategic move aligning with industry-wi…
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
NORTH CHICAGO, Ill., Sept. 29, 2026 // -- AbbVie (NYSE:ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.Through its…